Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Montfermeil – page 76

3 423 clinical trials in Montfermeil, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Montfermeil at a glance
3 423
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 423 trials in Montfermeil

Open in trial search

Study of Brigatinib for Children and Young Adults with ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors, or Other Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Brigatinib
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Study of Pembrolizumab with Chemotherapy for Patients with HER2-Negative Inflammatory Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Institut Paoli-Calmettes

Study on the Effects of Dornase Alfa for Patients with Subarachnoid Hemorrhage to Improve Independence After 6 Months

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dornase Alfa
  • Sponsor:Hopital Fondation Adolphe De Rothschild

Study on Atezolizumab and Bevacizumab for Patients with Intermediate-Stage Liver Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Neoplasm+1

Recruiting

Study of NVL-655 for Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with ALK Mutation

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:NVL-655
  • Sponsor:Nuvalent Inc.

Study of Elenestinib for Patients with Indolent Systemic Mastocytosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Elenestinib Phosphate
  • Sponsor:Blueprint Medicines Corp.

Prostate cancer+1

Recruiting

Study on Darolutamide, Triptorelin, and Leuprorelin Acetate for Patients with Newly Diagnosed Prostate Cancer and Pelvic Lymph Node Metastases

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:ARTIC

Study on the Safety and Effectiveness of MB-CART2019.1, Fludarabine, and Cyclophosphamide in Children with Relapsed or Refractory B Cell Neoplasms

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Cyclophosphamide
  • Sponsor:Miltenyi Biomedicine GmbH

Lupus nephritis

Recruiting

Study of Obinutuzumab and Mycophenolate Mofetil Without Oral Corticosteroids for Treatment of Lupus Nephritis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Assistance Publique Hopitaux De Paris

Study of High-Dose Vitamin C (Ascorbic Acid) Compared to Placebo in Patients with Sepsis and Acute Respiratory Distress Syndrome (ARDS) in Intensive Care

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Ascorbate
  • Sponsor:Assistance Publique Hopitaux De Paris

Study of asciminib treatment for patients with Chronic Myeloid Leukemia who have T315I mutation and cannot take or tolerate ponatinib

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Asciminib Hydrochloride
  • Sponsor:Novartis Pharma S.A.S.

Study on the Effects of Methylprednisolone and Prednisone for Treating Acute Flare-Ups in Idiopathic Pulmonary Fibrosis Patients

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:GIE Groupe hospitalier Paris Saint-Joseph/Vinci

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Montfermeil

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on acute myocarditis treatment and cardiac arrhythmia management. Research includes evaluation of corticosteroid therapy for improving left ventricular function and investigating preventive measures for premature ventricular complexes.

  • Myocarditis Treatment Optimization
  • Cardiac Function Management
  • Giant Cell Arteritis Studies

These trials aim to enhance treatment outcomes for patients with various cardiac conditions.

02 Respiratory Medicine

Advanced research in severe asthma management, exploring new biological therapies and treatment optimization strategies. Studies focus on comparing different therapeutic approaches for patients with eosinophilic phenotypes.

  • Asthma Biologics Evaluation
  • Treatment Duration Assessment
  • Therapeutic Monitoring

Investigations aim to improve long-term outcomes for patients with severe respiratory conditions.

03 Inflammatory Conditions

Comprehensive studies examining treatments for ulcerative colitis, sarcoidosis, and inflammatory eye conditions. Research includes innovative monitoring approaches and medication optimization.

  • Gastrointestinal Disorders
  • Autoimmune Conditions
  • Novel Treatment Strategies

Focus on improving patient outcomes through targeted therapies and personalized treatment approaches.

04 Rheumatology and Joint Health

Investigating innovative treatments for knee osteoarthritis and gout, particularly in patients with complex medical conditions. Studies explore new interventional procedures and medication alternatives.

  • Joint Disease Management
  • Pain Control Studies
  • Minimally Invasive Treatments

Research aims to enhance quality of life for patients with chronic joint conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.